Mohamed Mohamed O, Mamas Mamas A, Nagaraja Vinayak, Alraies M Chadi, Lamelas Pablo, Tzemos Nikolaos, Ayan Diana, Lavi Shahar, Bagur Rodrigo
University Hospital, London Health Sciences Centre, 339 Windermere Road, N6A 5A5, London, Ontario, Canada.
J Invasive Cardiol. 2019 Dec;31(12):E344-E355.
Percutaneous coronary intervention (PCI) of coronary bifurcation lesions (CBL) remains a challenge in contemporary practice due to the procedural and technical difficulties involved. We sought to review the current evidence on the safety and clinical outcomes of dedicated bifurcation stent (DBS) implantation in comparison with established treatment strategies for CBL-PCI.
We conducted a comprehensive search to identify randomized control trials (RCTs) reporting 1-year clinical and angiographic outcomes of patients undergoing CBL-PCI with DBS vs conventional CBL-PCI strategies. Random-effects meta-analyses were performed to estimate the effect of DBS compared with conventional CBL-PCI using aggregate data.
A total of 5 RCTs comprising 1249 participants met the inclusion criteria. The use of DBS was comparable to conventional stenting techniques in terms of major adverse cardiovascular event (MACE) rate (odds ratio [OR], 1.28; 95% confidence interval [CI], 0.90- 1.82; I²=0%), all-cause mortality (OR, 0.80; 95% CI, 0.31-2.07; I²=0%), cardiac mortality (OR, 0.16; 95% CI, 0.02-1.39; I²=0%), myocardial infarction (OR, 1.26; 95% CI, 0.84-1.89; I²=0%), definite stent thrombosis (OR, 1.75; 95% CI, 0.36-8.52; I²=0%), cumulative target-lesion revascularization (OR, 1.39; 95% CI, 0.85-2.27; I²=0%), clinically driven target-lesion revascularization (OR, 1.23; 95% CI, 0.68-2.22; I²=0%), or target-vessel revascularization (OR, 1.43; 95% CI, 0.92-2.22; I²=0%).
The present analysis suggests that CBL-PCI with DBS may be associated with similar 1-year clinical and angiographic outcomes compared with conventional CBL-PCI strategies. However, the low quality of evidence and limited follow-up warrant further studies to ascertain any significant differences in patient-important outcomes before the adoption of DBS into routine CBL-PCI practice.
由于涉及到操作和技术困难,冠状动脉分叉病变(CBL)的经皮冠状动脉介入治疗(PCI)在当代实践中仍然是一项挑战。我们试图回顾与CBL-PCI既定治疗策略相比,专用分叉支架(DBS)植入的安全性和临床结果的当前证据。
我们进行了全面检索,以确定报告接受CBL-PCI的患者采用DBS与传统CBL-PCI策略的1年临床和血管造影结果的随机对照试验(RCT)。使用汇总数据进行随机效应荟萃分析,以估计DBS与传统CBL-PCI相比的效果。
共有5项RCT(包括1249名参与者)符合纳入标准。在主要不良心血管事件(MACE)发生率(优势比[OR],1.28;95%置信区间[CI],0.90-1.82;I²=0%)、全因死亡率(OR,0.80;95%CI,0.31-2.07;I²=0%)、心脏死亡率(OR,0.16;95%CI,0.02-1.39;I²=0%)、心肌梗死(OR,1.26;95%CI,0.84-1.89;I²=0%)、明确的支架血栓形成(OR,1.75;95%CI,0.36-8.52;I²=0%)、累积靶病变血运重建(OR,1.39;95%CI,0.85-2.27;I²=0%)、临床驱动的靶病变血运重建(OR,1.23;95%CI,0.68-2.22;I²=0%)或靶血管血运重建(OR,1.43;95%CI,0.92-2.22;I²=0%)方面,DBS的使用与传统支架技术相当。
目前的分析表明,与传统CBL-PCI策略相比,采用DBS的CBL-PCI可能具有相似的1年临床和血管造影结果。然而,证据质量低和随访有限,需要进一步研究以确定在将DBS纳入常规CBL-PCI实践之前,患者重要结局方面是否存在任何显著差异。